Details of the Active Pharmaceutical Ingredient (API)

General Information of API (ID: D00685)
Name
Tolbutamide
Synonyms    Click to Show/Hide the Synonyms of This API
tolbutamide; 64-77-7; Orinase; Artosin; 1-Butyl-3-tosylurea; Tolbutamid; Aglicid; Arkozal; Diabetol; Dolipol; Rastinon; Tolumid; Diaben; Orabet; Tolylsulfonylbutylurea; Willbutamide; Butamide; Diabetamid; Diabuton; Diasulfon; Dirastan; Glyconon; Ipoglicone; Pramidex; Tolbusal; Artozin; Butamid; Drabet; Mobenol; Oralin; Orezan; Orinaz; Oterben; Toluina; Toluvan; 1-Butyl-3-(p-tolylsulfonyl)urea; Sk-tolbutamide; N-n-Butyl-N'-tosylurea; Tolbutamida; Tolbutamidum; N-(Butylcarbamoyl)-4-methylbenzenesulfonamide; 1-Butyl-3-(p-methylphenylsulfonyl)urea; 1-p-Toluenesulfonyl-3-butylurea; N-Butyl-N'-(p-tolylsulfonyl)urea; N-Butyl-N'-p-toluenesulfonylurea; 3-(p-Tolyl-4-sulfonyl)-1-butylurea; N-(4-Methylphenylsulfonyl)-N'-butylurea; N-Butyl-N'-(4-methylphenylsulfonyl)urea; N-(4-Methylbenzenesulfonyl)-N'-butylurea; HLS 831; Orinase (TN); Benzenesulfonamide, N-[(butylamino)carbonyl]-4-methyl-; N-(p-Tolylsulfonyl)-N'-butylcarbamide; N-(Sulfonyl-p-methylbenzene)-N'-N-butylurea; Urea, 1-butyl-3-(p-tolylsulfonyl)-; 1-butyl-3-(4-methylphenyl)sulfonylurea; NCI-C01763; N-4-Methylbenzolsulfonyl-N-butylurea; N-[(butylamino)carbonyl]-4-methylbenzenesulfonamide; N-Butyl-N'-toluene-p-sulfonylurea; UNII-982XCM1FOI; MFCD00027169; 1-Butyl-3-(4-methylphenylsulfonyl)urea; 3-butyl-1-(4-methylbenzenesulfonyl)urea; N-(p-Methylbenzenesulfonyl)-N'-butylurea; CHEMBL782; 982XCM1FOI; Benzenesulfonamide, N-((butylamino)carbonyl)-4-methyl-; MLS000028399; Arcosal; Beglucin; Butamidum; Diabesan; Tarasina; Tolbutone; CHEBI:27999; Tolbet; 1-BUTYL-3-(4-METHYLBENZENESULFONYL)UREA; N-((Butylamino)carbonyl)-4-methylbenzenesulfonamide; NSC-23813; CAS-64-77-7; NCGC00015999-10; SMR000058363; Tolbutamide form I^L^; DSSTox_CID_1359; DSSTox_RID_76106; DSSTox_GSID_21359; Tolbutamidum [INN-Latin]; Tolbutamida [INN-Spanish]; Tolumide; CCRIS 592; N-4-(Methylbenzolsulfonyl)-n-butylurea; NSC-87833; HSDB 3393; SR-01000003059; EINECS 200-594-3; NSC 23813; U 2043; (butylamino)-N-[(4-methylphenyl)sulfonyl]carboxamide; BRN 1984428; N-(Sulfonyl-p-methylbenzene)-N'-butylurea; tolbutamide IL; tolbutamide III; Tolbutamide [USP:INN:BAN:JAN]; Prestwick_471; PubChem18102; Spectrum_000447; Tolbutamide form I^H^; Opera_ID_112; 3-butyl-1-[(4-methylbenzene)sulfonyl]urea; Prestwick0_000190; Prestwick1_000190; Prestwick2_000190; Prestwick3_000190; Spectrum2_001210; Spectrum3_000599; Spectrum4_000358; Spectrum5_001272; Lopac-T-0891; N-n-Butyl-N''-tosylurea; WLN: 4MVMSWR D1; T 0891; NCIOpen2_009592; BIDD:PXR0179; CBiol_001920; Lopac0_001154; SCHEMBL15918; BSPBio_000119; BSPBio_001507; BSPBio_002078; KBioGR_000227; KBioGR_000795; KBioGR_002275; KBioSS_000227; KBioSS_000927; KBioSS_002276; 4-11-00-00396 (Beilstein Handbook Reference); MLS001148399; MLS002152944; Toluina; Tolumid; Orinase; DivK1c_000341; SPECTRUM1500581; SPBio_001000; SPBio_002040; BPBio1_000131; GTPL6848; Tolbutamide (JP17/USP/INN); Tolbutamide, analytical standard; DTXSID8021359; HMS501B03; KBio1_000341; KBio2_000227; KBio2_000927; KBio2_002275; KBio2_002795; KBio2_003495; KBio2_004843; KBio2_005363; KBio2_006063; KBio2_007411; KBio3_000453; KBio3_000454; KBio3_001578; KBio3_002755; cMAP_000008; NINDS_000341; 1-Butyl-3-(p-tolylsulfonoyl)urea; Bio1_000206; Bio1_000695; Bio1_001184; Bio2_000227; Bio2_000707; HMS1361L09; HMS1568F21; HMS1791L09; HMS1989L09; HMS2089C17; HMS2092M21; HMS2095F21; HMS2232H16; HMS3259A08; HMS3263H09; HMS3402L09; HMS3651N03; HMS3712F21; Pharmakon1600-01500581; BCP09192; HY-B0401; NSC23813; ZINC1530703; 1-n-Butyl-3-(p-tolylsulfonyl)urea; N-Butyl-N''-(p-tolylsulfonyl)urea; Tox21_110279; Tox21_201612; Tox21_302795; Tox21_501154; BDBM50027886; CCG-39141; NSC757354; SBB058188; 1-Butyl-3-(para-tolylsulfonyl)-urea; AKOS015894999; Tox21_110279_1; 1-(p-toluenesulfonyl)-3-n-butyl-urea; DB01124; LP01154; MCULE-9720356859; NC00543; NE30724; NSC-757354; SDCCGSBI-0051121.P004; Tolbutamide 1.0 mg/ml in Acetonitrile; IDI1_000341; IDI1_033977; N-(n-Butyl)-N'-p-toluene-sulfonylurea; NCGC00015999-01; NCGC00015999-02; NCGC00015999-03; NCGC00015999-04; NCGC00015999-05; NCGC00015999-06; NCGC00015999-07; NCGC00015999-08; NCGC00015999-09; NCGC00015999-11; NCGC00015999-12; NCGC00015999-13; NCGC00015999-14; NCGC00015999-15; NCGC00015999-16; NCGC00015999-17; NCGC00015999-19; NCGC00015999-20; NCGC00015999-29; NCGC00022721-03; NCGC00022721-04; NCGC00022721-05; NCGC00022721-06; NCGC00022721-07; NCGC00022721-08; NCGC00022721-09; NCGC00022721-10; NCGC00256548-01; NCGC00259161-01; NCGC00261839-01; AC-12490; AK115688; AS-14136; N-(4-Methylphenylsulfonyl)-N''-butylurea; N-Butyl-N''-(4-methylphenylsulfonyl)urea; SBI-0051121.P003; DB-054728; AB00052110; EU-0101154; FT-0603265; ST50409552; SW196681-3; BIM-0051121.0001; C07148; D00380; J10018; U-2043; AB00052110-16; AB00052110_17; AB00052110_18; Tolbutamide, VETRANAL(TM), analytical standard; Q414275; SR-01000003059-2; SR-01000003059-4; SR-01000003059-7; W-104820; BRD-K85119730-001-06-5; BRD-K85119730-001-17-2; Z44591715; Tolbutamide, European Pharmacopoeia (EP) Reference Standard; 1-(([(Butylamino)carbonyl]amino)sulfonyl)-4-methylbenzene #; Tolbutamide, United States Pharmacopeia (USP) Reference Standard
Clinical Status
Approved
Disease Indication Diabetes mellitus ICD-11: 5A10 [1]
PubChem CID
5505
Formula
C12H18N2O3S
Canonical SMILES
CCCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)C
InChI
1S/C12H18N2O3S/c1-3-4-9-13-12(15)14-18(16,17)11-7-5-10(2)6-8-11/h5-8H,3-4,9H2,1-2H3,(H2,13,14,15)
InChIKey
JLRGJRBPOGGCBT-UHFFFAOYSA-N
   Click to Show/Hide the Molecular Data (Structure/Property) of This API
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=5505"></iframe>
3D MOL 2D MOL
Physicochemical Properties Molecular Weight 270.35 Topological Polar Surface Area 83.6
XlogP 2.3 Complexity 354
Heavy Atom Count 18 Rotatable Bond Count 5
Hydrogen Bond Donor Count 2 Hydrogen Bond Acceptor Count 3
Full List of Drug Formulations (DFMs) Containing This API
          Tolbutamide 500 mg tablet Click to Show/Hide the Full List of Formulation(s):          1 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Sodium lauryl sulfate; Magnesium stearate; Silicon dioxide; Cellulose, microcrystalline; Sodium starch glycolate type a potato
                   Dosage Form Oral Tablet
                   Company Mylan Pharamceuticals
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Sodium lauryl sulfate DIG Info Solute carrier SLCO2B1 (Ki = 1.98 uM) [2]
Magnesium stearate DIG Info Albendazole monooxygenase (Protein expression downregulation) [3]
Silicon dioxide DIG Info Albendazole monooxygenase (Protein expression downregulation) [3]
References
1 FDA label for approved loxapine from the official website of the U.S. Food and Drug Administration.
2 Bacterial metabolism rescues the inhibition of intestinal drug absorption by food and drug additives. Proc Natl Acad Sci U S A. 2020 Jul 7;117(27):16009-16018.
3 Effects of commonly used excipients on the expression of CYP3A4 in colon and liver cells. Pharm Res. 2010 Aug;27(8):1703-12.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.